Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (NYSE: HIMS) is a health and wellness platform that regularly issues news about its digital care offerings, new specialties, and international growth. Company press releases highlight how the Hims and Hers brands use technology to connect customers with personalized care, with updates that span weight management, women’s health, labs and diagnostics, and broader platform developments.
Recent news has focused heavily on weight loss and metabolic health. Hims & Hers has launched a comprehensive Weight Loss Programme in the UK, including the official introduction of the Hers platform there, giving eligible women access to doctor-designed GLP‑1 treatment plans and holistic support for nutrition, movement, and sleep. In Canada, the company is entering the market through the acquisition of Livewell, a digital health platform focused on weight loss treatment, with plans to roll out an accessible, comprehensive weight loss program for Canadian customers.
Another key news theme is women’s health. The Hers platform has introduced a menopause and perimenopause specialty that offers eligible women access to treatment plans tailored to their health history and preferences, including prescription options such as estradiol and progesterone when deemed appropriate by licensed providers. News coverage also includes the launch of Labs, a testing experience that measures biomarkers across areas like heart health, metabolism, hormones, inflammation, and stress, pairing results with doctor-developed action plans.
Investors and followers of HIMS news will also see announcements about strategic acquisitions, such as the definitive agreement to acquire YourBio Health and its virtually painless TAP blood sampling technology, as well as corporate updates like share repurchase authorizations, financial results, leadership appointments, and facility investments. This news page aggregates these developments so readers can monitor how Hims & Hers is expanding its digital health platform, adding new capabilities, and executing its strategy across the United States, Europe, and Canada.
Hims & Hers Health, Inc. (NYSE: HIMS) has finalized its acquisition of Apostrophe, a teledermatology specialist. This strategic move aims to enhance the company's telehealth offerings, providing advanced, personalized dermatology treatments to consumers. The acquisition will strengthen Hims & Hers' dermatology business, with Apostrophe's team and its CEO, Ben Holber, joining Hims & Hers to lead this segment. The financial terms of the deal were not disclosed, but it reflects the company’s commitment to expand its healthcare services.
Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with Urban Outfitters, Inc. (NASDAQ: URBN) to offer personalized health and wellness solutions on urbanoutfitters.com. This collaboration will begin with select Hims products, expanding to include products from the Hers line, addressing skin care, hair loss, sexual health, and supplements. Melissa Baird, COO of Hims & Hers, emphasized the importance of consumer access to quality health products, while Jena Tracey from Urban Outfitters highlighted the synergy between their customer base and the personalized offerings of Hims & Hers.
Hims & Hers Health, NYSE: HIMS, has announced plans to acquire Apostrophe, a teledermatology specialist, enhancing its focus on personalized dermatology services. This strategic move aims to boost Hims & Hers' ability to deliver tailored treatment plans and expand its market presence, particularly among GenZ and Millennial consumers. Apostrophe's established clinical platform and licensed pharmacy in 29 states will facilitate faster, scalable delivery of dermatology treatments. The acquisition is anticipated to close in Q3 2023, with Apostrophe's CEO expected to lead the dermatology division.
Hims & Hers Health (NYSE: HIMS) has launched Minoxidil 5% Foam for both men and women, enhancing its hair regrowth product line. This FDA-approved treatment is clinically-proven to regrow hair in 3 to 6 months and works by increasing blood flow to hair follicles, activating hair growth, and extending the growth phase. The addition of this foam option responds to customer demand for convenient hair loss solutions. Global superstar Jennifer Lopez endorses this launch, emphasizing the importance of personalized self-care.
Hims & Hers Health, Inc. (NYSE: HIMS) has been awarded the title of D-To-C Brand of the Year by Ad Age, recognizing its innovative approach in the telehealth sector. The award highlights Hims & Hers' commitment to personalized health and wellness solutions, particularly during the COVID-19 pandemic. CEO Andrew Dudum emphasized the importance of this recognition among notable brands. The Creativity Awards focus on impactful contributions in marketing, with Hims & Hers being lauded for its consumer-centric model and disruption of traditional healthcare.
Hims & Hers Health announces its strategic acquisition of Honest Health, a UK-based health platform specializing in hair loss products. This deal aims to bolster Hims & Hers' operational capabilities and support its expansion into the UK and Western Europe. Honest Health, founded in 2018, offers innovative health solutions through a partnership with a UK compounding pharmacy. The acquisition is expected to close in the second fiscal quarter of 2021, aligning with Hims & Hers' mission to enhance personalized healthcare experiences for consumers.
Hims & Hers has appointed multi-platinum artist Miley Cyrus as a Creative Advisor. She will collaborate on the Hers line of prescription skincare products, enhancing their marketing efforts. Miley emphasizes the importance of personalized skincare, a sentiment echoed by Co-Founder and CEO Andrew Dudum, who aims to demystify skincare routines for consumers. The company provides telehealth consultations and customizable prescription products, focusing on acne and anti-aging treatments. Established in 2017, Hims & Hers operates across all 50 states, offering accessible healthcare solutions.
Hims & Hers has launched a new Topical Finasteride & Minoxidil Spray, a pill-free treatment for male pattern hair loss. This innovative spray combines 6% minoxidil and 0.1% finasteride to effectively block DHT production and promote hair regrowth. The product addresses customer demand for alternative delivery methods to oral medications, providing a drip-free, easy-to-use option. Customers can access this treatment via a telehealth consultation with a licensed medical professional.
Hims & Hers has introduced The Blur Stick, a skincare product for men, in partnership with Alex Rodriguez. Designed to provide quick coverage for blemishes and dark circles, this new concealer features premium ingredients like jojoba oil and aloe extract. Available in eight shades, The Blur Stick retails for $22 and emphasizes convenience in design and use. Rodriguez, a co-investor, highlighted the need for accessible, quality men's skincare products. Hims & Hers aims to break stigmas in men's grooming with this innovative offering.
Hims & Hers Health, a telehealth platform (NYSE: HIMS), will conduct its virtual annual shareholders' meeting on June 17, 2021, at 10:00 a.m. PT.
A live audio webcast will be available on the company’s investor site. Shareholders are invited to participate via this link and must follow the proxy statement procedures to submit questions and vote.
Hims & Hers, established in November 2017, offers accessible healthcare services across various specialties, promoting quality care for mental, sexual, and dermatological health.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
